Therapeutic Use Exemption (TUE) Checklist



Female Infertility Prohibited Substances: Clomiphene, Letrozole





201-2723 chemin Lancaster Rd Ottawa ON Canada K1B 0B1 Tel/Tél + 1 613 521 3340 + 1 800 672 7775 Fax/Téléc + 1 613 521 3134 info@cces.ca www.cces.ca

This checklist provides the athlete and their physician with a list of requirements for a TUE application. A TUE application must include a completed form and a medical file that confirms the diagnosis and prescription. If it is not possible to submit all mandatory items on the checklist, please have the treating physician explain why.

A complete application with a medical file will be reviewed by the CCES TUE Committee to assess whether it meets the criteria of the International Standard for Therapeutic Use Exemption (ISTUE). There are no guarantees that a TUE will be granted.

When an application is submitted without a complete medical file the CCES will advise the applicant which documents are missing and ask them to submit them.

TUE application form must include:
□ All sections completed in legible handwriting
All information submitted in English or French
□ A signature from the prescribing physician
Athlete's signature in all appropriate sections
A letter from athlete's prescribing physician confirming they were seen within the current year (see Annex 1 for example)
Medical reports should include details of:
□ Medical history: menstrual history, previous pregnancy or miscarriage, sexually transmitted infection (STI),
gynaecological medical conditions, or surgery
Symptoms of endocrine disturbance such as hirsutism, acne, galactorrhea, hot flushes and sweating, or fatigue
 General physical examination including a gynaecological examination
 Lifestyle factors and chronic diseases that can affect fertility
Response to previous treatment(s) (ovulation monitoring, ovulation stimulation, IVF)
A list of past and/or current therapies
Diagnostic test results should include copies of:
Relevant laboratory tests (ovarian reserve testing, such as serum analysis of anti-müllerian hormone (AMH) and follicle-
stimulating hormone (FSH) on cycle day 3 to 5 together with AFC by ultrasound)
Imaging findings (e.g., vaginal ultrasound, HyCoSy, HSG, laparoscopy, hysteroscopy)

For more information about WADA's ISTUE criteria and additional information about the documentation to be submitted, please visit WADA's TUE Physician Guidelines - Female Infertility.